GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (LSE:BXP) » Definitions » Cyclically Adjusted Revenue per Share

Beximco Pharmaceuticals (LSE:BXP) Cyclically Adjusted Revenue per Share : £0.21 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beximco Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2024 was £0.165. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is £0.21 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Beximco Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 17.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Beximco Pharmaceuticals was 17.80% per year. The lowest was 13.10% per year. And the median was 17.40% per year.

As of today (2024-06-09), Beximco Pharmaceuticals's current stock price is £0.385. Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was £0.21. Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.83.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.12. The lowest was 1.63. And the median was 2.74.


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Beximco Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.18 0.19 0.23 0.14

Beximco Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.14 0.14 0.17 0.21

Competitive Comparison of Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beximco Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.165/131.7762*131.7762
=0.165

Current CPI (Mar. 2024) = 131.7762.

Beximco Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.040 98.790 0.053
201312 0.043 98.326 0.058
201403 0.039 99.695 0.052
201406 0.041 100.560 0.054
201409 0.044 100.428 0.058
201412 0.044 99.070 0.059
201503 0.045 99.621 0.060
201506 0.049 100.684 0.064
201509 0.051 100.392 0.067
201512 0.050 99.792 0.066
201609 0.059 101.861 0.076
201612 0.058 101.863 0.075
201703 0.057 102.862 0.073
201706 0.061 103.349 0.078
201709 0.064 104.136 0.081
201712 0.065 104.011 0.082
201803 0.063 105.290 0.079
201806 0.073 106.317 0.090
201809 0.081 106.507 0.100
201812 0.086 105.998 0.107
201903 0.086 107.251 0.106
201906 0.089 108.070 0.109
201909 0.086 108.329 0.105
201912 0.093 108.420 0.113
202003 0.099 108.902 0.120
202006 0.098 108.767 0.119
202009 0.104 109.815 0.125
202012 0.112 109.897 0.134
202103 0.110 111.754 0.130
202106 0.116 114.631 0.133
202109 0.127 115.734 0.145
202112 0.127 117.630 0.142
202203 0.134 121.301 0.146
202206 0.131 125.017 0.138
202209 0.147 125.227 0.155
202212 0.148 125.222 0.156
202303 0.143 127.348 0.148
202306 0.150 128.729 0.154
202312 0.164 129.419 0.167
202403 0.165 131.776 0.165

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Beximco Pharmaceuticals  (LSE:BXP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.385/0.21
=1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.12. The lowest was 1.63. And the median was 2.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Beximco Pharmaceuticals (LSE:BXP) Business Description

Traded in Other Exchanges
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.